Guardant Health (GH) PT Raised to $40 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Guardant Health (GH) PT Raised to $40 at Jefferies
August 7, 2024 4:05 PM EDT
Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds
Shield approved by FDA as primary option for CRC screening and is commercially available in U.S.
PALO ALTO, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024.
Second Quarter 2024 Financial Highlights
Revenue of $177.2 million for the second quarter of 2024, an increase of 29% over the second quarter of 2023
Reported 49,400 tests to...
More
August 7, 2024 8:05 AM EDT
Largest study to date evaluating MRD detection using tissue-free approach demonstrates 81% longitudinal sensitivity for recurrence in stage II or higher colon cancer
Data demonstrate potential clinical utility of ctDNA as tool to improve management of stage II and higher CRC that allows for rapid evaluation without complexity of prior tissue analysis
PALO ALTO, Calif.--(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Clinical Cancer Research, a journal of the American Association for Cancer Research, will publish... More
